Related Experiment Video
Updated: Jun 14, 2026

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
Published on: February 23, 2024
Clinicogenomic Landscape of Histologic Subtypes in Ovarian Cancer: Real-World Evidence From a Japanese Nationwide
Ryuji Tamaki1, Hiroyuki Kogai1, Koji Sagane1
1Tsukuba Research Laboratories, Eisai Co, Ltd, Tsukuba, Ibaraki, Japan.
Purpose:
The frequency of histologic subtypes in epithelial ovarian cancer (EOC) varies by geographic region. In Western countries, high-grade serous ovarian cancer (HGSOC) is the most common and well characterized, whereas non-HGSOC subtypes, particularly clear cell ovarian cancer (CCOV), are more prevalent in Asia. However, their clinicogenomic features remain poorly defined.
Patients And Methods:
This retrospective study analyzed real-world data from Japan's Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database. The cohort included 5,395 patients diagnosed with ovarian cancer between January 2016 and June 2025. Clinical characteristics, treatment patterns, and real-world overall survival (rwOS) were evaluated in histologic subtypes. Comprehensive genomic profiling was used to characterize mutational landscapes and to identify genomic biomarkers associated with rwOS.
Results:
EOCs were classified into five histologic subtypes: HGSOC (51%), low-grade serous (LGSOC; 2.7%), CCOV (30%), endometrioid (EOV; 8.9%), and mucinous (MOV; 7.3%). Compared with Western cohorts, HGSOC was less frequent and CCOV more prevalent. Distinct mutational profiles were observed across subtypes: TP53 mutations in 94% of HGSOC, frequent ARID1A and PIK3CA mutations in CCOV and EOV, KRAS mutations in LGSOC and MOV, and enriched CDKN2A and CDKN2B deletions in MOV. KEAP1 and NFE2L2 mutations in HGSOC and CCOV, respectively, increased in post-treatment tumors, suggesting ferroptosis-mediated therapeutic resistance. Biomarker analyses identified subtype-specific associations with rwOS: PIK3CA mutations in HGSOC and CDKN2A/CDKN2B deletions in CCOV, EOV, and MOV with shorter rwOS, BRCA1, and BRCA2 alterations in HGSOC with longer rwOS. A subclass of TP53 mutations that destabilize p53 protein structure was associated with shorter survival in HGSOC and EOV.
Conclusion:
This large clinicogenomic study in an Asian population highlights unique mutational landscapes and survival associations, which may inform personalized treatment strategies.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Related Concept Videos
Cancer Survival Analysis
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancers Originate from Somatic Mutations in a Single Cell